文献速递类风湿关节炎

老年类风湿关节炎患者合并甲氨蝶呤治疗降低对SARS-CoV-2 mRNA疫苗第三剂(加强针)的体液免疫应答

Reduced humoral response to a third dose (booster) of SARS-CoV-2 mRNA vaccines by concomitant methotrexate therapy in elderly patients with rheumatoid arthritis.
PubMed 文献 · RMD Open · 2022-01-01

该研究比较了136例类风湿关节炎患者对SARS-CoV-2 mRNA疫苗第三剂(加强针)的体液免疫应答,发现老年患者中合并甲氨蝶呤治疗者的抗RBD IgG显著低于b/tsDMARDs单药或甲氨蝶呤单药治疗者,而年轻患者中合并甲氨蝶呤无显著影响;作者认为老年患者第三剂接种期间可考虑暂停甲氨蝶呤。

要点

  • 老年RA患者合并甲氨蝶呤治疗后第三剂mRNA疫苗的抗RBD IgG显著低于b/tsDMARDs单药或甲氨蝶呤单药。
  • 年轻RA患者(<64.5岁)中合并甲氨蝶呤对体液免疫应答无显著影响。
  • 作者认为老年RA患者第三剂接种期间可考虑暂停甲氨蝶呤。

核心结论

  • 合并甲氨蝶呤增加老年RA患者对SARS-CoV-2疫苗体液免疫应答不足的风险。
  • 作者认为该组患者第三剂接种期间可考虑暂停甲氨蝶呤。

研究设计与样本

  • 比较136例接受甲氨蝶呤和/或b/tsDMARDs治疗的RA患者对SARS-CoV-2疫苗的体液免疫应答。
  • 在第三剂BNT162b2或mRNA-1273接种后中位52.5天(范围2-147天)检测靶向SARS-CoV-2刺突蛋白RBD的IgG。

主要发现

  • 老年患者中,合并甲氨蝶呤组抗RBD IgG为64.8(20.8, 600.3)BAU/mL,b/tsDMARDs单药组为1106.0(526.3, 4965.2)BAU/mL,甲氨蝶呤单药组为1743.8(734.5, 6779.6)BAU/mL,中位数(IQR),p<0.001,Kruskal-Wallis检验。
  • 年轻患者(<64.5岁)中,合并甲氨蝶呤对体液免疫应答无显著影响。

临床怎么用

  • 作者认为老年RA患者第三剂疫苗接种期间可考虑暂停甲氨蝶呤。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Several health authorities recommend a third (booster) vaccination to protect patients with rheumatic and musculoskeletal diseases from severe COVID-19. Methotrexate has been shown to reduce the efficacy of the first and second dose of SARS-CoV-2 mRNA vaccines. So far, it remains unknown how concomitant methotrexate affects the efficacy of a COVID-19 booster vaccination. METHODS: We compared the humoral immune response to SARS-CoV-2 vaccination in 136 patients with rheumatoid arthritis (RA) treated with methotrexate and/or biological or targeted synthetic (b/tsDMARDs). IgG targeting the receptor binding domain (RBD) of SARS-CoV-2 spike protein was measured at a median of 52.5 (range 2-147) days after a third dose of the SARS-CoV-2 mRNA vaccines BNT162b2 or mRNA-1273. RESULTS: Anti-RBD IgG was significantly reduced in elderly patients receiving concomitant treatment with methotrexate as compared with elderly patients receiving monotherapy with b/tsDMARDs or methotrexate (64.8 (20.8, 600.3) binding antibody units per mL (BAU/mL) vs 1106.0 (526.3, 4965.2) BAU/mL vs 1743.8 (734.5, 6779.6) BAU/mL, median (IQR), p<0.001, Kruskal-Wallis test). In younger patients (< 64.5 years), concomitant methotrexate had no significant impact on the humoral immune response. CONCLUSIONS: Concomitant methotrexate increases the risk of an insufficient humoral immune response to SARS-CoV-2 vaccination in elderly patients with RA. Pausing methotrexate during the third vaccination period may be considered for this group of patients.

来源:RMD Open,查看原文。版权归原作者所有。

引用

  1. Stahl D, Tho Pesch C, Brück C, et al. Reduced humoral response to a third dose (booster) of SARS-CoV-2 mRNA vaccines by concomitant methotrexate therapy in elderly patients with rheumatoid arthritis. RMD Open. 2022. PMID: 36216409. doi:10.1136/rmdopen-2022-002632

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。